Osteoarthritis Immune System: How Inflammation Destroys Joints

Immune Cells, Inflammatory Mediators and New Therapies

More than 500 million people worldwide live with osteoarthritis (OA). Most of them have heard the same explanation from their doctor: “Your cartilage is wearing down. It’s part of aging.” While this is partially true, a growing body of science tells a far more complex and actionable story.

A landmark 2026 review published in Immunity & Inflammation by He and colleagues now confirms what researchers have long suspected: osteoarthritis is not simply a mechanical disease. It is an immune-mediated disorder in which your own body’s defense system turns against your joints. Understanding the osteoarthritis immune system connection opens entirely new doors for treatment and gives patients and healthcare providers a more accurate map of what’s really happening inside an arthritic joint.

This article synthesizes the most current evidence from six high-quality scientific publications to explain, in plain language, how immune cells, inflammatory mediators, and dysregulated signaling pathways drive joint destruction and what promising new therapies are emerging to stop them.

Why Osteoarthritis Is Now Classified as an Immune-Mediated Disease

For most of the 20th century, OA was treated as an inevitable consequence of mechanical wear. Cartilage breaks down, bone rubs on bone, and pain follows. This view led to a largely symptom-focused approach: pain management, joint replacement and rest.

The problem with this model is that it doesn’t explain why some people develop severe OA quickly while others with similar mechanical wear barely progress. It also fails to account for a key observation: active inflammation is consistently present in OA joints, even in early stages.

A pivotal 2025 review in Nature Reviews Rheumatology by Moulin and colleagues highlights that technological advances in the past five years have revealed remarkable diversity among immune cells in the OA joint, particularly in the synovium (the membrane lining the joint) and the infrapatellar fat pad (the fatty cushion beneath the kneecap). The presence of synovial lymphoid structures, circulating autoantibodies and altered T cell and B cell populations in OA patients suggests that the disease has genuine autoimmune features — blurring the once sharp line between “inflammatory arthritis” and “degenerative arthritis.”

This reclassification matters enormously for treatment. If OA is immune-driven, then targeting the immune system, not just the mechanical damage , becomes a legitimate and potentially curative strategy.

Understanding how cartilage molecules are affected by this immune process is essential background for grasping why immune control is so critical to joint survival.

The Seven Immune Cells That Drive Joint Destruction

At the center of the osteoarthritis immune system story are seven distinct types of immune cells. Each plays a specific role in the destructive process. According to He et al. (2026), these cells “orchestrate a destructive immune-bone crosstalk within the joint microenvironment.”

Here is how each cell type contributes:

1. Macrophages — The most important immune players in OA. When activated chronically, they produce pro-inflammatory cytokines that eat away at cartilage. They exist in two main states: M1 (pro-inflammatory, destructive) and M2 (anti-inflammatory, repair-promoting). In OA, the balance tips overwhelmingly toward M1. Research in Frontiers in Immunology (2024) confirms that macrophages in OA synovium show persistent M1 polarization, sustaining the inflammatory cycle.
2. T Lymphocytes (Th1, Th2, Th17, Treg cells) — T cells are the commanders of adaptive immunity. In OA, the balance between pro-inflammatory Th17 cells and regulatory Treg cells is severely disrupted. Th17 cells secrete IL-17, which drives osteoclast (bone-eroding cell) formation and amplifies production of TNF-α and IL-1β. This imbalance between Th17 and Treg populations is now recognized as a central driver of OA progression.
3. B Lymphocytes — Healthy B cells produce osteoprotegerin (OPG), a molecule that protects bone by blocking osteoclast activity. In OA, this protective function is compromised, allowing bone erosion to proceed unchecked.
4. Natural Killer (NK) Cells — NK cells secrete interferon-γ (IFN-γ), which suppresses bone formation pathways including the critical Wnt/β-catenin and BMP/Smad signaling routes. This disrupts the normal bone repair process.
5. Dendritic Cells (DCs) — DCs act as messengers between the innate and adaptive immune systems. In OA joints, they present joint-derived antigens to T cells, potentially triggering the autoimmune-like cascade described above.
6. Neutrophils — These rapid-response cells infiltrate the synovial fluid during OA flares. They release proteolytic enzymes, particularly matrix metalloproteinases (MMPs), that directly degrade the cartilage matrix.
7. Mast Cells (MCs) — Mast cells release histamine, proteases, and cytokines that amplify synovial inflammation and accelerate cartilage breakdown. Their numbers are significantly elevated in OA synovial tissue.

The combined action of these seven cell populations creates what researchers now call the bone-immune crosstalk, a self-reinforcing circuit of destruction that, without intervention, becomes progressively worse over time.

Inflammatory Mediators: The Chemical Messages of Destruction

Understanding which chemicals these immune cells release helps explain exactly how joint inflammation translates into cartilage loss and bone damage.

The 2026 review by He et al. identifies four key inflammatory mediators as central to OA pathogenesis:

TNF-α (Tumor Necrosis Factor-alpha) is one of the earliest and most powerful drivers of OA. TNF-α activates multiple downstream signaling pathways, promotes osteoclast formation and works synergistically with other inflammatory molecules to accelerate bone erosion. It is one of the primary targets of existing biologic drugs (like anti-TNF therapies currently used in rheumatoid arthritis), and researchers are now exploring similar applications in OA.

IL-1β (Interleukin-1 beta) is perhaps the most studied cytokine in OA. IL-1β activates NF-κB, PI3K/AKT and MAPK pathways simultaneously. It stimulates chondrocytes to produce MMP-13, an enzyme that degrades type II collagen , the main structural protein of articular cartilage. IL-1β also plays a dual role in bone destruction, both stimulating osteoclast precursors directly and increasing RANKL expression in osteoblasts.

IL-6 (Interleukin-6) drives osteoclast differentiation through MAPK, NF-κB and AP-1 signaling. In the context of T cell biology, IL-6 is the critical switch that determines whether naïve CD4+ T cells differentiate into destructive Th17 cells rather than protective Treg cells.

TGF-β (Transforming Growth Factor-beta) plays a complex and somewhat paradoxical role. In healthy joints, TGF-β promotes cartilage repair. In OA, chronically elevated TGF-β disrupts normal bone remodeling and contributes to osteophyte (bone spur) formation.

Importantly, a 2025 study published in Biomolecules emphasizes that these inflammatory mediators don’t just damage joints, they also sensitize pain pathways, both peripherally in the joint and centrally in the nervous system. This explains why OA pain often persists and intensifies even when visible joint damage appears stable, and why the pain experience varies so dramatically between patients with similar X-ray findings.

For patients interested in how the gut microbiome relates to this inflammatory process, our article on gut microbiome and osteoarthritis provides important additional context.

Pathogenic Signaling Pathways: The Molecular Machinery of OA

If immune cells are the soldiers and cytokines are their orders, then signaling pathways are the command-and-control infrastructure that translates those orders into cellular action. Three pathways stand out in the current OA literature.

The NF-κB Pathway

Nuclear Factor-kappa B (NF-κB) is the master regulator of inflammation. A comprehensive 2023 review in Signal Transduction and Targeted Therapy (Nature Portfolio) describes NF-κB as extensively involved in OA pathology through multiple mechanisms. When pro-inflammatory cytokines like TNF-α and IL-1β bind to their receptors on chondrocyte surfaces, they activate NF-κB, which then switches on genes for:

• Matrix metalloproteinases (MMP-1, MMP-3, MMP-13) that degrade cartilage collagen
• Additional pro-inflammatory cytokines (creating a self-amplifying loop)
• RANKL, which drives osteoclast formation and bone erosion
• COX-2, the enzyme responsible for prostaglandin-driven pain and inflammation

This is why NF-κB has been described as a “master switch” for OA — activating it starts a cascade that is very difficult to stop once established.

The Wnt/β-Catenin Pathway

The Wnt/β-catenin pathway regulates tissue development and homeostasis. In healthy joints, it operates at carefully controlled levels to maintain cartilage and bone. In OA, it becomes chronically overactivated. The 2023 Signal Transduction review notes that elevated β-catenin in articular chondrocytes drives them toward a hypertrophic (enlarged, dysfunctional) state, accelerating cartilage matrix breakdown.

What makes Wnt signaling particularly exciting as a therapeutic target is that at least one clinical-stage drug, SM04690, a small-molecule Wnt inhibitor, has already advanced to phase I clinical trials, demonstrating early signals of efficacy in knee OA.

The MAPK Pathway

The Mitogen-Activated Protein Kinase (MAPK) pathway operates downstream of IL-1β and TNF-α signaling. It regulates expression of catabolic genes through three main branches: ERK1/2, p38, and JNK. MAPK also functions as a pain mediator, making it relevant not just to cartilage biology but to the neurological experience of chronic OA pain. Research in Biomolecules (2025) identifies MAPK inhibition as one of the most promising avenues for drugs that simultaneously address structural damage and pain sensitization.

Key Insight: These three pathways — NF-κB, Wnt/β-catenin, and MAPK — are not independent. They form an interconnected network. Blocking one pathway without considering the others often leads to compensatory upregulation. This is why future OA therapies will likely need to target multiple pathways simultaneously.

Therapeutic Strategies: From Mechanism to Medicine

The growing understanding of OA as an immune-driven disease has catalyzed a new generation of therapeutic approaches. He et al. (2026) and Moulin et al. (2025) both highlight three major treatment categories showing clinical promise.

1. Immunomodulatory Therapy

This approach uses drugs to specifically modulate, not broadly suppress, the immune response in OA joints. Current strategies under investigation include:

• Anti-TNF-α biologics: Already transformative in rheumatoid arthritis, these drugs are being studied in inflammatory OA phenotypes.
• IL-1β inhibitors: Agents like anakinra (an IL-1 receptor antagonist) have shown benefit in crystal-induced arthritis and are being evaluated in OA.
• IL-6 pathway blockers: Tocilizumab, which blocks the IL-6 receptor, is under investigation in OA patients with high synovial inflammation.
• JAK inhibitors: These small molecules block the JAK-STAT pathway, which sits downstream of multiple cytokine receptors, offering broad anti-inflammatory effects with a single oral drug.

The challenge with immunomodulatory therapy is precision — OA is not one disease but a spectrum of subtypes with different dominant immune mechanisms. Matching the right drug to the right patient profile remains an active research priority.

2. Mesenchymal Stem Cell (MSC) Therapy

MSC therapy represents one of the most exciting frontiers in OA treatment. These cells, derived from bone marrow, fat tissue (adipose) or umbilical cord, do far more than simply generate new cartilage. They produce a rich secretome of anti-inflammatory molecules, immunomodulatory factors and growth factors that actively reset the joint microenvironment.

The 2025 Journal of Inflammation Research review notes that MSCs suppress macrophage polarization toward the destructive M1 phenotype and promote the shift toward M2 (reparative) macrophages. They also suppress Th17 cell activity while supporting Treg populations, directly addressing the T cell imbalance that drives OA progression.

For an in-depth exploration of how adipose-derived stem cells work specifically in knee OA, see our article on adipose-derived stem cells for knee pain relief. And if you want a broader comparison of why regenerative approaches are gaining ground over traditional treatments, read our guide on why PRP and stem cells are outperforming traditional OA treatments.

3. Small-Molecule Pathway Inhibitors (Disease-Modifying OA Drugs — DMOADs)

This category targets the specific molecular switches identified in the signaling pathway research. Key candidates include:

• NF-κB inhibitors: Multiple agents are in development, including IKK complex inhibitors that prevent the activation cascade from initiating.
• Wnt pathway modulators: SM04690 (lorecivivint) is the most advanced, showing intra-articular injection feasibility in early trials.
• p38 MAPK inhibitors: These address both structural damage and pain, making them particularly interesting for OA management.
• AMPK activators: AMPK acts as a cellular energy sensor that, when activated, suppresses NF-κB and MAPK inflammation while promoting cartilage anabolism.

The concept of a true disease-modifying osteoarthritis drug (DMOAD) — one that demonstrably slows or reverses joint structural damage — has been the holy grail of OA research for decades. For the first time, the scientific understanding of immune-signaling mechanisms makes this goal appear realistically achievable within the next five to ten years.

Platelet-Rich Plasma (PRP) therapy, which harnesses the natural growth factors and anti-inflammatory molecules in your own blood, is already an established clinical tool in this landscape. You can learn more in our detailed guide on PRP therapy for knee pain.

Emerging Frontiers: Single-Cell Analysis and Personalized Medicine

A 2025 review in ScienceDirect using single-cell RNA sequencing (scRNA-seq) technology has mapped the OA immune microenvironment at unprecedented resolution. This technology reveals that immune cells in OA joints are not uniform populations, they are highly heterogeneous, with distinct subpopulations that differ in their inflammatory behavior, stage of activation, and sensitivity to treatment.

For example, scRNA-seq has identified specific IL-17A+ Th17 cell subtypes that drive cartilage degradation through MMP-13 upregulation, and TGF-β1+ macrophage-fibroblast activation axes that drive joint fibrosis. Knowing exactly which subpopulations are dominant in a given patient’s joint could, in the near future, guide precision medicine approaches, selecting the right drug for the right immune profile.

This single-cell technology also intersects with the emerging understanding of exosomal microRNAs, tiny molecular packages released by cells (including MSCs) that regulate gene expression in target cells. A 2025 systematic review confirms that MSC-derived exosomal miRNAs, particularly miR-146a and NF-κB modulators, show strong preclinical evidence for suppressing OA-related inflammation in both in vitro and animal models.

Conclusion

The science is clear: osteoarthritis is not just about worn-out cartilage. It is a complex immune-mediated disease in which macrophages, T cells, NK cells, and other immune populations orchestrate a self-sustaining cycle of joint destruction. Key inflammatory mediators — TNF-α, IL-1β, and IL-6 — act as molecular accelerators, while dysregulated signaling pathways like NF-κB and Wnt/β-catenin keep the destruction running.

The good news is that this mechanistic clarity is now translating directly into therapeutic innovation. Immunomodulatory biologics, MSC-based regenerative therapies, and DMOAD small molecules are all advancing through the pipeline. For the first time, it appears genuinely possible to develop treatments that don’t just manage OA pain but modify the disease course itself.

For anyone living with joint pain, or for healthcare professionals treating OA patients, this shift in understanding is profound. The question is no longer just “how do we manage the damage?” It is “how do we stop the immune attack before the damage occurs?”

If you found this article valuable, explore related topics on our site — including the surprising link between gut bacteria and joint health and the science behind stem cell therapy for joint repair. The picture of OA as a whole-body, immune-mediated condition continues to grow and the treatment options are growing with it.

References

1. He Z, Hao H, Chen B, Li X, Mao D, Jin Y, Zhao K, Chen G. Pathogenesis and therapeutic strategies of osteoarthritis: roles of immune cells, inflammatory mediators, and pathogenic signaling pathways. Immunity & Inflammation. 2026;2:3. doi: 10.1007/s44466-025-00022-0
2. Moulin D, Sellam J, Berenbaum F, Guicheux J, Boutet MA. The role of the immune system in osteoarthritis: mechanisms, challenges and future directions. Nat Rev Rheumatol. 2025;21(4):221–36. doi: 10.1038/s41584-025-01223-y
3. Fan D, Mao Z, Wang Q, et al. Osteoarthritis: pathogenic signaling pathways and therapeutic targets. Signal Transduct Target Ther. 2023;8(1):56. doi: 10.1038/s41392-023-01330-w
4. Liu S, Yuan H, Liu M, et al. The role of Th/Treg immune cells in osteoarthritis. Front Immunol. 2024;15:1393418. doi: 10.3389/fimmu.2024.1393418
5. Osteoimmunology in Osteoarthritis: Unraveling the Interplay of Immunity, Inflammation, and Joint Degeneration. J Inflamm Res. 2025. PMC: 11930281
6. [Authors]. Unraveling Osteoarthritis: Mechanistic Insights and Emerging Therapies Targeting Pain and Inflammation. Biomolecules. 2025;15(6):874. doi: 10.3390/biom15060874